Structured evidence table for Lutein Visual Performance Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Lutein Visual Performance Randomized Trial | However, these approaches require repeated invasive injections and are associated with considerable economic burden and procedural risks [,]. | 1 | Wang Wei-Xiang (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials |
| Lutein Visual Performance Randomized Trial | Experimental and clinical studies have suggested that increased macular pigment levels may support visual performance and potentially attenuate AMD progression [–]. | 1 | Wang Wei-Xiang (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials |
| Lutein Visual Performance Randomized Trial | Some findings from the Age‐Related Eye Disease Study 2 (AREDS2) indicated that lutein and zeaxanthin supplementation significantly reduced the risk of progression to late‐stage AMD []. | 1 | Wang Wei-Xiang (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials |
| Lutein Visual Performance Randomized Trial | 1 2 3 4 5 6 7 Age‐related macular degeneration (AMD) remains one of the leading causes of irreversible central vision loss among individuals over 65 years of age worldwide. | 1 | Wang Wei-Xiang (2026) | From Supplements to Sight: Quantifying the Impact of Lutein and Carotenoid on Age‐Related Macular Degeneration—A Systematic Review and Meta‐Analysis of Randomized Controlled Trials |
Source documents